Startup profile · funding coverage
Switchpoint Bio funding, valuation and investors
Developing blood-based DNA-methylation profiling and AI to monitor disease biology and treatment response for drug developers.
Verified company research · funding, investors and latest developments
Keep track of Switchpoint Bio
Save this profile to your VCT watchlist for a quick return.
Funding, valuation & investors
Answer-first snapshotLatest funding
Pre-seed (issuer release dateline; precise legal close unknown)
$5.3M · November 10, 2026
Latest known valuation
Undisclosed
Pre-seed (issuer release dateline; precise legal close unknown) · November 10, 2026
Total disclosed equity funding
$5.3M
Excludes debt, grants, acquisitions, secondaries, and IPO proceeds.
Current status
private
pre seed · Helsinki, Finland and Cambridge, Massachusetts, US
Investors in latest funding
Lead: Treehouse Delmar Investments
Overview
Switchpoint Bio, founded in 2025 and operating in Helsinki and Cambridge, Massachusetts, develops targeted DNA-methylation assays in circulating immune cells, interpreted with single-cell reference datasets and AI. It seeks to make disease-state and drug-response changes measurable in repeat blood draws. Its first validation effort includes lupus research, with pharma collaborations under discussion. On Nov.
11, 2026 a company-issued Finnish wire with a Nov. 10 internal dateline disclosed a $5.3M pre-seed including a $5M investment from Treehouse Delmar.
Why Switchpoint Bio is interesting
A company-issued November 11 Finnish release reports $5.3M pre-seed financing, including $5M from Treehouse Delmar Investments. Its assay is moving toward clinical and industry validation rather than a proven or approved diagnostic. A longitudinal blood test could potentially reduce the burden of repeated complex sampling, but that remains an unproven commercial claim.
Product & use cases
Research-stage assay/workflow, not a clinical service: illustrative pharmaceutical collaborator (1) defines disease cohort and treatment endpoints; (2) collects serial blood samples before and after intervention; (3) profiles targeted DNA methylation in circulating immune cells; (4) maps those signals onto single-cell reference/biobank data using analysis models; (5) tests correlations with treatment response and resistance in controlled validation studies; (6) investigates reproducibility, sensitivity and clinical utility before any routine deployment. The issuer says lupus is an early research focus. No validated clinical performance, approved diagnostic, product price or pharma customer contract was disclosed.
- R&D biomarker monitoring for a systemic lupus erythematosus clinical study, subject to validation.
- Drug-developer exploratory analysis of treatment-related immune cell-state changes.
- Longitudinal cohort studies aiming to infer disease biology from less invasive blood samples, not a proven replacement for tissue biopsy.
Key facts
- Original issuer release published Nov 11, 2026 12:45 EET, with internal Nov 10 dateline; no legal close date stated.
- $5.3M pre-seed total; Treehouse Delmar contributes $5M of this total, not in addition.
- Research platform uses targeted DNA methylation, single-cell reference data and AI; clinical and industry validation is pending.
Funding history (newest first)
Pre-seed (issuer release dateline; precise legal close unknown)
2026-11-10 $5.3M Valuation: Undisclosed- Treehouse Delmar Investments (lead)
Source: Read source · sttinfo.fi
Competitive landscape
Edge: Potential ability to repeatedly profile disease-relevant immune-cell states through standard blood samples versus expensive/disruptive tissue or single-cell workflows; not independently validated at scale.
Alternative single-cell sequencing may deliver rich cell-resolution biology but is operationally intensive. Conventional plasma biomarkers can be easier to run yet may not reveal the same epigenetic signatures. The hypothesis of Switchpoint's targeted methylation assay is biologically plausible, but the company must establish pre-analytical stability, cross-cohort robustness, effects of immune cell composition, concordance with disease states, pharmacodynamic specificity, validation cost and clinical utility before claims about routine care.
-
10x Genomics adjacent
Single-cell and spatial genomic tools for rich research characterization, which can be more complex and costly for longitudinal sample use.
-
Illumina incumbent
Sequencing instruments and assays supporting many genomic/epigenomic workflows; not an identical turnkey biomarker service.
-
Guardant Health adjacent
Commercial blood-based molecular testing mainly oncology; different biomarkers and validation pathway.
-
Tempus adjacent
Clinical/genomic data analytics and diagnostics with a distinct current product scope.
Notable stories
- Primary, company-issued Finnish wire sttinfo.fi (external source) published Nov 11 with Nov 10 dateline.
- Additional original reporting eu-startups.com (external source) 11 November.
Market / IPO context
Editorial / static context — not a live quote.
FAQs about Switchpoint Bio
Practical answers founders, operators, and investors typically search for.
Last updated:
Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.